Here's How An Options Trader Made $5.5 Million In One Day

Madrigal Pharmaceuticals Inc MDGL shares rose sharply on Monday after the company announced positive topline results from the pivotal Phase 3 MAESTRO-NASH (fatty liver disease) biopsy trial of resmetirom.

On CNBC’s "Options Action," Mike Khouw of Optimize Advisors said traders bought 559 January 110-calls at $12 per contract on Friday.

Don’t forget to check out our premarket coverage here. 

Those calls traded at $120 per contract on Monday, which implies that traders saw a profit of around $5.5 million in just one trading day, Khouw mentioned.

MDGL Price Action: Shares of Madrigal Pharmaceuticals jumped 268.1% to close at $234.83 in the regular trading session on Monday, and rose another 0.5% in after-hours trading.

Check This Out: Over $13 Million Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying